Evaluate the Safety, Tolerability, Pharmacokinetic Profile, Efficacy of Bl-M11D1
Public ClinicalTrials.gov record NCT06714591. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Open-Label Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of BL-M11D1 in Patients With Relapsed/Refractory Acute Myeloid Leukemia.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The objective of this study to evaluate the safety, tolerability, pharmacokinetic profile, and preliminary efficacy of BL-M11D1 in patients with relapsed/refractory acute myeloid leukemia.
Study identification
- NCT ID
- NCT06714591
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 52 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 18, 2024
- Primary completion
- Sep 15, 2026
- Completion
- Sep 15, 2026
- Last update posted
- Sep 23, 2026
2024 – 2026
United States locations
- U.S. sites
- 18
- U.S. states
- 15
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| City of Hope | Duarte | California | 91010 | — |
| UCLA Ronald Reagan Medical Center | Los Angeles | California | 90095 | — |
| University of Colorado Anschutz Medical Campus | Aurora | Colorado | 80045 | — |
| Yale Cancer Center, Smilow Cancer Hospital at Yale New Haven | New Haven | Connecticut | 06511 | — |
| Moffitt Cancer Center | Tampa | Florida | 33612 | — |
| Northwestern Memorial Hospital | Chicago | Illinois | 60611 | — |
| The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Baltimore | Maryland | 21287 | — |
| START Midwest/The Cancer and Hematology Center | Grand Rapids | Michigan | 49546 | — |
| John Theurer Cancer Center-Hackensack | Hackensack | New Jersey | 07601 | — |
| Oncology Hematology Care Clinical Trials, LLC | Cincinnati | Ohio | 45236 | — |
| The Ohio State University Comprehensive Cancer Center | Columbus | Ohio | 43210 | — |
| WVCI Oncology Associates of Oregon | Eugene | Oregon | 24224 | — |
| Oregon Health and Science University | Portland | Oregon | 97239 | — |
| Temple Health Fox Chase Cancer Center | Philadelphia | Pennsylvania | 19111 | — |
| SCRI -TriStar BMT | Nashville | Tennessee | 37203 | — |
| MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| Virginia Cancer Specialists | Fairfax | Virginia | 22031 | — |
| Fred Hutchinson Cancer Center | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06714591, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 23, 2026 · Synced Sep 28, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06714591 live on ClinicalTrials.gov.